In breast cancer, SIRT2 inhibits the acetylation of GSK3β in CD8(+) effector memory T cells, leading to an increase in the number of effector memory T cells, enhancing the tumour immune response and slowing tumour progression.73 Here, SIRT2 is linked to breast carcinoma.